Emerging treatments
Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Vogl DT et al. Clin Cancer Res. 2017 Jan 4. pii: clincanres.2526.2016. doi: 10.1158/1078-0432.CCR-16-2526. [Epub ahead of print]. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137). Simões-Pires CA et al. Expert Opin Ther Pat. 2017 Jan 16. doi: 10.1080/13543776.2017.1282945.…